TY - JOUR
T1 - Cancer prevention and therapy through the modulation of the tumor microenvironment
AU - Casey, Stephanie C.
AU - Amedei, Amedeo
AU - Aquilano, Katia
AU - Azmi, Asfar S.
AU - Benencia, Fabian
AU - Bhakta, Dipita
AU - Bilsland, Alan E.
AU - Boosani, Chandra S.
AU - Chen, Sophie
AU - Ciriolo, Maria Rosa
AU - Crawford, Sarah
AU - Fujii, Hiromasa
AU - Georgakilas, Alexandros G.
AU - Guha, Gunjan
AU - Halicka, Dorota
AU - Helferich, William G.
AU - Heneberg, Petr
AU - Honoki, Kanya
AU - Keith, W. Nicol
AU - Kerkar, Sid P.
AU - Mohammed, Sulma I.
AU - Niccolai, Elena
AU - Nowsheen, Somaira
AU - Vasantha Rupasinghe, H. P.
AU - Samadi, Abbas
AU - Singh, Neetu
AU - Talib, Wamidh H.
AU - Venkateswaran, Vasundara
AU - Whelan, Richard L.
AU - Yang, Xujuan
AU - Felsher, Dean W.
N1 - Funding Information:
R.L.W. is conducting a Phase I trial for EGCG. The authors thank the Italian Ministry of University and Research (2009FZZ4XM_002 to E.N., A.A.), the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (S.P.K.), the National Institutes of Health (R01CA128704 to D.H.), National Institutes of Health F32CA177139, R01CA170378, U54CA149145, P50CA114747, R01CA184384, and R21CA169964 (to S.C.C., D.W.F.), an NIH R15 CA137499-01 (F.B.), a startup fund from Ohio University, an RSAC grant ( RP1206 ) from the Heritage College of Osteopathic Medicine at OU (to F.B.), Prostate and Ovarian Cancer Research Trust in Surrey, UK (S. Chen), a Connecticut State University Research grant (S. Crawford), an EU Marie Curie Reintegration Grant MC-CIG-303514 , Greek National funds through the Operational Program ‘Educational and Lifelong Learning of the National Strategic Reference Framework (NSRF)-Research Funding Program: THALES (Grant number MIS 379346 ) and COST Action CM1201 ‘Biomimetic Radical Chemistry’ (to A.G.G.), the Charles University in Prague projects UNCE 204015 and PRVOUK P31/2012 , by the Czech Science Foundation project P301/12/1686 , and by the Internal Grant Agency of the Ministry of Health of the Czech Republic project NT13663-3/2012 (to P.H.), the Ministry of Education, Culture, Sports, Science and Technology, Japan (No. 24590493 ) (to K.H.), and private donations (R.L.W.). W.N.K. and A.E.B. acknowledge the University of Glasgow, Beatson Oncology Centre Fund, CRU ( www.cancerresearchuk.org/ ) grant C301/A14762 . Study sponsors had no involvement in the study. The authors also acknowledge the efforts of Leroy Lowe and the Getting to Know Cancer team.
Funding Information:
R.L.W. is conducting a Phase I trial for EGCG. The authors thank the Italian Ministry of University and Research (2009FZZ4XM_002 to E.N., A.A.), the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (S.P.K.), the National Institutes of Health (R01CA128704 to D.H.), National Institutes of Health F32CA177139, R01CA170378, U54CA149145, P50CA114747, R01CA184384, and R21CA169964 (to S.C.C., D.W.F.), an NIH R15 CA137499-01 (F.B.), a startup fund from Ohio University, an RSAC grant (RP1206) from the Heritage College of Osteopathic Medicine at OU (to F.B.), Prostate and Ovarian Cancer Research Trust in Surrey, UK (S. Chen), a Connecticut State University Research grant (S. Crawford), an EU Marie Curie Reintegration Grant MC-CIG-303514, Greek National funds through the Operational Program ‘Educational and Lifelong Learning of the National Strategic Reference Framework (NSRF)-Research Funding Program: THALES (Grant number MIS 379346) and COST Action CM1201 ‘Biomimetic Radical Chemistry’ (to A.G.G.), the Charles University in Prague projects UNCE 204015 and PRVOUK P31/2012, by the Czech Science Foundation project P301/12/1686, and by the Internal Grant Agency of the Ministry of Health of the Czech Republic project NT13663-3/2012 (to P.H.), the Ministry of Education, Culture, Sports, Science and Technology, Japan (No. 24590493) (to K.H.), and private donations (R.L.W.). W.N.K. and A.E.B. acknowledge the University of Glasgow, Beatson Oncology Centre Fund, CRU (www.cancerresearchuk.org/) grant C301/A14762. Study sponsors had no involvement in the study. The authors also acknowledge the efforts of Leroy Lowe and the Getting to Know Cancer team.
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Cancer arises in the context of an in vivo tumor microenvironment. This microenvironment is both a cause and consequence of tumorigenesis. Tumor and host cells co-evolve dynamically through indirect and direct cellular interactions, eliciting multiscale effects on many biological programs, including cellular proliferation, growth, and metabolism, as well as angiogenesis and hypoxia and innate and adaptive immunity. Here we highlight specific biological processes that could be exploited as targets for the prevention and therapy of cancer. Specifically, we describe how inhibition of targets such as cholesterol synthesis and metabolites, reactive oxygen species and hypoxia, macrophage activation and conversion, indoleamine 2,3-dioxygenase regulation of dendritic cells, vascular endothelial growth factor regulation of angiogenesis, fibrosis inhibition, endoglin, and Janus kinase signaling emerge as examples of important potential nexuses in the regulation of tumorigenesis and the tumor microenvironment that can be targeted. We have also identified therapeutic agents as approaches, in particular natural products such as berberine, resveratrol, onionin A, epigallocatechin gallate, genistein, curcumin, naringenin, desoxyrhapontigenin, piperine, and zerumbone, that may warrant further investigation to target the tumor microenvironment for the treatment and/or prevention of cancer.
AB - Cancer arises in the context of an in vivo tumor microenvironment. This microenvironment is both a cause and consequence of tumorigenesis. Tumor and host cells co-evolve dynamically through indirect and direct cellular interactions, eliciting multiscale effects on many biological programs, including cellular proliferation, growth, and metabolism, as well as angiogenesis and hypoxia and innate and adaptive immunity. Here we highlight specific biological processes that could be exploited as targets for the prevention and therapy of cancer. Specifically, we describe how inhibition of targets such as cholesterol synthesis and metabolites, reactive oxygen species and hypoxia, macrophage activation and conversion, indoleamine 2,3-dioxygenase regulation of dendritic cells, vascular endothelial growth factor regulation of angiogenesis, fibrosis inhibition, endoglin, and Janus kinase signaling emerge as examples of important potential nexuses in the regulation of tumorigenesis and the tumor microenvironment that can be targeted. We have also identified therapeutic agents as approaches, in particular natural products such as berberine, resveratrol, onionin A, epigallocatechin gallate, genistein, curcumin, naringenin, desoxyrhapontigenin, piperine, and zerumbone, that may warrant further investigation to target the tumor microenvironment for the treatment and/or prevention of cancer.
KW - Cancer biology
KW - Cancer prevention
KW - Cancer therapy
KW - Tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=84926430176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926430176&partnerID=8YFLogxK
U2 - 10.1016/j.semcancer.2015.02.007
DO - 10.1016/j.semcancer.2015.02.007
M3 - Review article
C2 - 25865775
AN - SCOPUS:84926430176
SN - 1044-579X
VL - 35
SP - S199-S223
JO - Seminars in Cancer Biology
JF - Seminars in Cancer Biology
ER -